Business Wire

YAMAHA

Share
Yamaha: Japanese-style Music Education Using Recorders Begins at Public Primary Schools in India

In cooperation with the Delhi Board of School Education, Yamaha Corporation (below, "Yamaha") introduced Japanese-style instrumental music education using recorders for grade V students at ten public primary schools in India in April. Programs using recorders and keyboards have been offered as extra-curriculum activities at private primary schools in India since 2017, but this is the first time a program will be offered as part of public primary school classes. The program offered by Yamaha not only includes technical recorder instruction, but also incorporates groupwork and discussion within classes to cultivate mutual understanding. Preceding the start of the classes, music teacher training is being conducted with an emphasis on using a holistic learning approach. Yamaha aims to expand the program to more schools in Delhi in the future. “Introduction of Japanese-style music education in primary education in India” was adopted by MEXT as a 2022 EDU-Port Japan*1 Supported Project.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230511005424/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Classes at public primary school in India

About School Project

As a comprehensive musical instruments manufacturer, Yamaha has been promoting the advantages of music and instrumental music education to music education sites around the world. In particular, Yamaha’s School Project, which it has been developing principally in emerging countries since 2015, is an initiative with the aim of popularizing activities using music and musical instruments in public education to convey the joy of music and musical instruments. To date, Yamaha has provided a total of 2,020,000 children (as of March 2023) in seven countries—Malaysia, Indonesia, Vietnam, India, Brazil, the United Arab Emirates, and Egypt—with opportunities to learn instrumental music, helping to create an environment where children can enjoy music and playing musical instruments.

Through this activity, Yamaha aims to contribute to Goal 4: "Quality Education," Goal 10: “Reduced Inequalities,” Goal 16: “Peace, Justice and Strong Institutions,” and Goal 17: "Partnerships for the Goals" of the Sustainable Development Goals (SDGs), as well as to develop children's non-cognitive skills through music and instrumental music education and to formulate a business model for musical education activities tailored to the educational situation in schools around the world.

Comments from Yasuhiro Yonehara, First Secretary, Embassy of Japan in India

Walking through the streets of India, one can hear music along with the bustling of the city. In Bollywood films, actors can be seen dancing joyfully to upbeat songs. Indian people are very familiar with music, and I feel that music is an integral part of their lives. How exciting it is when Indian children pick up a recorder, an unfamiliar instrument, learn to play it and create music. I sincerely wish that this initiative, which is making this possible, will be a huge success.

*1 EDU-Port Japan is a “public-private, nationwide” initiative to introduce Japanese-style education overseas using the public-private collaborative platform, supported by Japan’s Ministry of Education, Culture, Sports, Science and Technology (MEXT).

https://www.yamaha.com/en/about/activities/school_project/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005424/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye